SecBot SecBot
SECBOTREPLAY Home › Report › KURA

KURA · Q3 KOMZIFTI rev $13.9M +53%

Kura Oncology, Inc. · PRESS-RELEASE filed Nov 10, 2026 at 16:02 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Nov 10, 2026 at 16:02 ET

Kura Oncology reported Q3 2026 results with KOMZIFTI net product revenue of $13.9M, up 53% sequentially, and a net loss of $70.2M ($0.78 per share) versus consensus EPS of -$0.81. The company also announced FDA alignment on a darlifarnib registrational study and a $300M Oberland Capital financing facility.

  • KOMZIFTI net product revenue $13.9M in Q3 2026, up 53% from Q2 2026
  • Net loss $70.2M ($0.78 per share) vs consensus EPS -$0.81
  • Total revenue $22.8M (product $13.9M + collaboration $8.9M)
  • Cash and investments $492.1M as of Sep 30, 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access